Orexo announces last patient enrolled in pivotal study evaluating the efficacy of MODIA® in combination with sublingual buprenorphine/ naloxone for the treatment of OUD
· Study evaluating efficacy of MODIA®, a digital therapeutic, in addition to clinician supervised medication-assisted treatment programs for individuals with opioid usedisorder (OUD) · The study enrolled 437 participants at 35 sites across the US · Orexo brings deep category expertise to the research effort, having served the US OUD market extensively over the last nine years Uppsala, Sweden – October 28, 2022 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces the last participant has enrolled in the pivotal study of the digital therapeutic MODIA® as part of a